TABLE 1.
Details of clinical trials on drug candidates against COVID-19.
| Intervention/treatment | Study type/Phase | Primary purpose | Number of participants | Sponsor (ClinicalTrials.gov Identifier) | |
| 1 | Remdesivir | Interventional | Treatment | 453 | Capital Medical University (NCT04257656) |
| 2 | Remdesivir | Interventional | Treatment | 308 | (Capital Medical University) NCT04252664 |
| 3 | Remdesivir | Expanded Access | Treatment | U.S. Army Medical Research and Development Command (NCT04302766) | |
| 4 | Remdesivir | Interventional | Treatment | 400 | Gilead Sciences (NCT04292899) |
| 5 | Remdesivir | Interventional | Treatment | 600 | Gilead Sciences (NCT04292730) |
| 6 | Remdesivir | Expanded Access | Treatment | - | Gilead Sciences (NCT04323761) |
| 7 | Remdesivir | Interventional | Treatment | 440 | National Institute of Allergy and Infectious Diseases (NCT04280705) |
| 8 | Hydroxychloroquine | Interventional Phase 3 | Treatment | 440 | Medical University of Vienna (NCT04336748) |
| 9 | Hydroxychloroquine Remdesivir | Interventional | Treatment | 700 | Oslo University Hospital (NCT04321616) |
| 10 | Chloroquine/hydroxychloroquine | Interventional Phase 2 | Prevention | 55000 | Washington University School of Medicine (NCT04333732) |
| 11 | Chloroquine phosphate | Interventional | Treatment | 250 | Oxford University Clinical Research Unit, Vietnam (NCT04328493) |
| 12 | Chloroquine | Interventional Phase 2, Phase 3 | Treatment | 210 | HaEmek Medical Center, Israel (NCT04333628) |
| 13 | Chloroquine phosphate | Interventional Phase 3 | Treatment | 400 | Wrocław Medical University |
| (NCT04331600) | |||||
| 14 | Chloroquine or Hydroxychloroquine | Interventional | Prevention | 4000 | University of Oxford (NCT04303507) |
| 15 | Chloroquine analog, Nivolumab, Tocilizumab | Interventional Phase 2 | Treatment | 273 | Centre Leon Berard (NCT04333914) |
| 16 | Chloroquine Diphosphate | Interventional Phase 2 | Treatment | 440 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (NCT04323527) |
| 17 | Azithromycin and Chloroquine | Interventional Phase 3 | Treatment | 1500 | Population Health Research Institute (NCT04324463) |
| 18 | Azithromycin, Hydroxychloroquine | Interventional Phase 4 | Treatment | 226 | Chronic Obstructive Pulmonary Disease Trial Network, Denmark (NCT04322396) |
| 19 | Darunavir and hydroxychloroquine | Interventional Phase 3 | Treatment | 3040 | Fundacio Lluita Contra la SIDA (NCT04304053) |
| 20 | Hydroxychloroquine | Interventional Phase 3 | Treatment | 2486 | Gangnam Severance Hospital (NCT04330144) |
| 21 | Hydroxychloroquine Sulfate | Interventional | Treatment | 220 | University Hospital, Akershus (NCT04316377) |
| 22 | Hydroxychloroquine azithromycin | Interventional Phase 3 | Treatment | 440 | Hospital Israelita Albert Einstein (NCT04321278) |
| 23 | Hydroxychloroquine | Interventional | Treatment | 1300 | University Hospital, Angers (NCT04325893) |
| 24 | Levamisole, Budesonide, Formoterol, Lopinavir/Ritonavir hydroxychloroquine | Interventional Phase2 and 3 | Treatment | 30 | Fasa University of Medical Sciences (NCT04331470) |
| 25 | Carrimycin lopinavir/ritonavir Arbidol, chloroquine phosphate | Interventional Phase 4 | Treatment | 520 | Beijing YouAn Hospital (NCT04286503) |
| 26 | Oseltamivir, Hydroxychloroquine LopipinavirRitonavir, Darunavir Favipiravir | Interventional Phase 3 | Treatment | 80 | Rajavithi Hospital (NCT04303299) |
| 27 | Favipiravir | Interventional | Treatment | 210 | Peking University First Hospital (NCT04333589) |
| 28 | Favipiravir | Interventional Phase 3 | Treatment | 100 | Giuliano Rizzardini (NCT04336904) |
| 29 | Arbidol | Interventional Phase 4 | Treatment | 380 | Jieming QU (NCT04260594) |
| 30 | ASC09(novel investigational protease inhibitor) lopinavir/ritonavir | Interventional | Treatment | 160 | First Affiliated Hospital of Zhejiang University (NCT04261907) |
| 31 | Lopinavir/ritonavir Hydroxychloroquine sulfate | Interventional phase 2 | Treatment | 150 | Asan Medical Center (NCT04307693) |
| 32 | Lopinavir/ritonavir | Interventional phase 2 | Treatment | 440 | Sunnybrook Health Sciences Centre (NCT04330690) |
| 33 | Hydroxychloroquine Lopinavir/ritonavir | Interventional Phase 3 | Treatment | 1200 | Centre Hospitalier Universitaire de Saint Etienne (NCT04328285) |
| 34 | Hydroxychloroquine Oseltamivir Azithromycin | Interventional Phase 3 | Treatment | 500 | Shehnoor Azhar (NCT04338698) |
| 35 | lopinavir/ritonavir Hydroxychloroquine Sulfate Losartan | Interventional Phase 2,3 | Treatment | 4000 | Bassett Healthcare (NCT04328012) |
| 36 | Abidol hydrochloride, Oseltamivir Lopinavir/ritonavir | Interventional Phase 4 | Treatment | 400 | Tongji Hospital |
| (NCT04255017) | |||||
| 37 | Lopinavir/ritonavir tablets Xiyanping injection | Interventional | Treatment | 80 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. (NCT04295551) |
| 38 | lopinavir/ritonavir and Traditional Chinese Medicines | Interventional | Treatment | 150 | Beijing 302 Hospital (NCT04251871) |
| 39 | Methylprednisolone | Interventional Phase 2 | Treatment | 104 | University of Trieste (NCT04323592) |
| 40 | Colchicine | Interventional Phase 3 | Treatment | 2500 | Estudios Clínicos Latino América (NCT04328480) |
| 41 | Angiotensin 1-7 | Interventional Phase 2/3 | Treatment | 60 | Erasme University Hospital(NCT04332666) |
| 42 | Thalidomide | Interventional Phase 2 | Treatment | 40 | First Affiliated Hospital of Wenzhou Medical University (NCT04273581) |
| 43 | Thalidomide | Interventional Phase 2 | Treatment | 100 | First Affiliated Hospital of Wenzhou Medical University NCT04273529 |
| 44 | Dietary Supplement: Natural Honey | Interventional Phase 3 | Treatment | 1000 | Misr University for Science and Technology (NCT04324489) |